Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
01/26/01	₩59,200.00	-8.92%	1,51,982
31/26/31	₩65,000.00	-1.52%	1,36,530
28/26/28	₩66,000.00	-1.20%	60,446
27/26/27	₩66,800.00	-2.05%	74,330
26/26/26	₩68,200.00	-3.54%	82,186

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 01/09/2026			5-day change	1st Jan Change
59,200.00 ^KRW	-8.92%		-18.34%	-50.67%

23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
15/07	Alert wrongly tagged to Orum Therapeutics withdrawn	RE

Market Cap	1,28600Cr 93Cr 81Cr 76Cr 69Cr 129.99Cr 8.88TCr 130.89Cr 899.67Cr 349.61Cr 4.51TCr 351.15Cr 343.57Cr 15TCr	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	1,17900Cr 86Cr 74Cr 70Cr 64Cr 119.17Cr 8.14TCr 119.99Cr 824.73Cr 320.49Cr 4.14TCr 321.9Cr 314.95Cr 14TCr	EV / Sales 2024 *	-	EV / Sales 2025	1,03,580x
Free-Float	84.16%	Yield 2024 *	-	Yield 2025	-

23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
15/07	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
18/04	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
13/04	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
16/01	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
05/01	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
18/12	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
04/11	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/25/15	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/25/23	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/25/07	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/24/16	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

23/08	Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate	AQ
19/12	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
15/25/15	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Share Price

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation : Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news : Orum Therapeutics, Inc.

Press Releases : Orum Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-8.92%
1 week	-18.34%
Current month	-8.92%
1 month	+32.74%
3 months	-12.68%
6 months	-54.57%
Current year	-50.67%

1 week	58,500	72,800
1 month	42,400	75,700
Current year	36,100	1,46,600
1 year	25,750	1,46,600
3 years	15,950	1,46,600
5 years	15,950	1,46,600
10 years	15,950	1,46,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	17/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	23/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	05/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	17/08/2016
In-Tae Jeong BRD	Director/Board Member	44	23/10/2023
Un-Nam Park BRD	Director/Board Member	55	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/02/25	Seung-Ju Lee	Free	Founder	33,88,000	-
21/02/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
21/02/25	Un-Nam Park	Free	Director	60,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	-8.92%	-18.34%	+130.35%	-	103.1Cr
WUXI APPTEC CO., LTD.	-0.25%	-0.92%	+49.47%	+89.45%	6.81TCr
ARGENX SE	+1.21%	+2.55%	+46.72%	+90.66%	6.36TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.31%	+1.81%	+49.04%	+12.07%	2.56TCr
INSMED INCORPORATED	-0.25%	-1.99%	-10.72%	+455.09%	2.66TCr
BIONTECH SE	+0.33%	-9.64%	+1.95%	-15.70%	2.55TCr
PHARMAESSENTIA CORPORATION	-6.09%	-11.19%	+224.80%	+351.08%	1.82TCr
GENMAB A/S	+1.18%	+1.66%	+35.20%	-18.67%	1.97TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.35%	+7.84%	+540.26%	1.52TCr
EXELIXIS, INC.	+4.12%	+4.29%	+52.03%	+154.09%	1.35TCr
Average	-0.89%	-4.78%	+58.67%	+184.26%	2.77TCr
Weighted average by Cap.	+0.11%	-2.90%	+47.31%	+145.57%

	2024	2025
Net sales	2.09TCr 1.52Cr 1.31Cr 1.23Cr 1.13Cr 2.11Cr 144.37Cr 2.13Cr 15Cr 5.68Cr 73Cr 5.71Cr 5.59Cr 244.17Cr	2.36Cr 17.13T 14.8T 13.9T 12.7T 23.82T 16.27L 23.99T 2L 64.07T 8L 64.35T 62.96T 27.52L
Net income	-574.01Cr -41.73L -36.05L -33.87L -30.94L -58.03L -40Cr -58.43L -4.02Cr -1.56Cr -20Cr -1.57Cr -1.53Cr -67Cr	-4.2TCr -3.05Cr -2.64Cr -2.48Cr -2.26Cr -4.24Cr -289.83Cr -4.27Cr -29Cr -11Cr -147.35Cr -11Cr -11Cr -490.18Cr
Net Debt	-9.05TCr -6.58Cr -5.68Cr -5.34Cr -4.88Cr -9.15Cr -624.77Cr -9.21Cr -63Cr -25Cr -317.64Cr -25Cr -24Cr -1.06TCr	-11TCr -7.79Cr -6.73Cr -6.32Cr -5.77Cr -11Cr -739.64Cr -11Cr -75Cr -29Cr -376.04Cr -29Cr -29Cr -1.25TCr